Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
The Promise of In Vivo CAR T Cell Therapies
/in Not PCa related/by MaxPlant Virus-Based Cancer Immunotherapy: A New Frontier in Fighting Cancer
/in Oncolytic, Preclinical Research/by MaxPSA Level at 6 Months as a Predictor of Long-Term Outcomes: Real 10-Year Overall Survival Data from the CHAARTED Trial
/in Post-hoc/by MaxAlpha DaRT: A Promising Frontier in the Treatment of Prostate, Bladder, and Advanced Cancers
/in Clinical Trial, Localized, Metastatic/by MaxStatins Linked to Improved Survival in Advanced Prostate Cancer Patients on Apalutamide
/in Post-hoc, Retrospective studies/by MaxOMNIRAY: a Phase 1 Clinical Trial for LY4257496 for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxThe OMNIRAY trial will be investigating LY4257496, a novel radioligand therapy and it is set to begin in August 2025. This phase 1a/1b, multicenter, open-label study aims to establish the safety, tolerability and dosimetry of LY4257496 in adult patients bearing advanced solid tumors that express the gastrin-releasing peptide receptor (GRPR). The trial proposes a two-part […]
Nutrition and Inflamation: New Research Unveils Five Universal Patient Clusters in Oncology
/in Retrospective studies/by MaxNuanced Benefits of Fasting-Mimicking Diets: High Protein vs. Low Protein
/in Clinical Trial/by MaxA recent study published in Clinical Nutrition sheds new light on the physiological impacts of Fasting-Mimicking Diets (FMDs), revealing that while both low-protein and high-protein versions offer significant health advantages, their specific benefits can differ notably. This randomized controlled trial explored the effects of a 7-day plant-based FMD with either a low protein/high fat (LP-FMD) […]